— Catalyst Pharmaceutical (NASDAQ: CPRX) reported third quarter 2019 earnings of $0.13 per share, vs. $0.11 per share expected.
— Net product revenue came in at $30.9 million, vs. $33.2 million expected.
— Expects full year 2019 revenues of approx. $100 million. Revenues in 2020 projected to be in the range of $135 million to $155 million.
— CPRX shares fell 5.2% immediately following the announcement.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
